Anetumab ravtansine: Phase II started

Bayer began an open-label, international Phase II trial to compare 6.5 mg/kg IV anetumab ravtansine every 3 weeks vs. IV vinorelbine once weekly in about 183 patients. The start triggered an undisclos...